Acute myeloid leukemia (AML) carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc؉ AML) accounts for about one-third of adult AML and shows distinct features, including a unique gene expression profile. MicroRNAs (miRNAs) are small noncoding RNAs of 19 -25 nucleotides in length that have been linked to the development of cancer. Here, we investigated the role of miRNAs in the biology of NPMc؉ AML. The miRNA expression was evaluated in 85 adult de novo AML patients characterized for subcellular localization/ mutation status of NPM1 and FLT3 mutations using a custom microarray platform. Data were analyzed by using univariate t test within BRB tools. We identified a strong miRNA signature that distinguishes NPMc؉ mutated (n ‫؍‬ 55) from the cytoplasmic-negative (NPM1 unmutated) cases (n ‫؍‬ 30) and includes the up-regulation of miR-10a, miR-10b, several let-7 and miR-29 family members. Many of the down-regulated miRNAs including miR-204 and miR-128a are predicted to target several HOX genes. Indeed, we confirmed that miR-204 targets HOXA10 and MEIS1, suggesting that the HOX upregulation observed in NPMc؉ AML may be due in part by loss of HOX regulators-miRNAs. FLT3-ITD؉ samples were characterized by upregulation of miR-155. Further experiments demonstrated that the up-regulation of miR-155 was independent from FLT3 signaling. Our results identify a unique miRNA signature associated with NPMc؉ AML and provide evidence that support a role for miRNAs in the regulation of HOX genes in this leukemia subtype. Moreover, we found that miR-155 was strongly but independently associated with FLT3-ITD mutations.
A cute myeloid leukemia (AML) arises from multiple and sequential genetic alterations involving hematopoietic precursors (1) . In Ϸ25% of cases, specific chromosomal translocations like the t(8;21), inv (16) or t (15;17) represent the initial events leading to malignant transformation (1) and are associated with a good outcome. In contrast, 40-50% of AMLs have normal karyotype by conventional banding analysis and are characterized by great molecular and clinical heterogeneity (2) . Recent work has identified novel molecular abnormalities in normal karyotype AML (NK-AML) that has improved the classification and risk stratification of this large subgroup of patients. Among them, internal tandem duplications in the juxta-membrane domain or mutations in the second tyrosine kinase domain (TKD) of the FLT3 gene have been found in 30-45% of NK-AML (3) . Both types of mutations constitutively activate FLT3 and FLT3-ITD mutations have been associated with increased risk of relapse (4) . Mutations in the myeloid transcription factor CEBPA have been detected in 10-15% of NK-AML (5) and are associated with favorable prognosis (5, 6) .
Mutations of the nucleophosmin (NPM1) gene, usually occurring at exon-12 (7) and more rarely at exon-11 (8) represent the most common genetic alteration in AML-NK (50-60% of cases) and account for about one-third of all adult AML (7) . This gene encodes for a ubiquitously expressed nucleolar protein (NPM1 or B23) that shuttles between the nucleus and cytoplasm and is implicated in multiple functions, including ribosomal protein assembly and transport, control of centrosome duplication and regulation of Arf tumor suppressor gene integrity (9) . NPM1 mutations result in the relocalization of NPM1 from the nucleus into the cytoplasm (7), hence the term NPMcϩ (cytoplasmic-positive) AML. NPMcϩ AML with displays distinctive features including mutual exclusion with AML with recurrent genetic abnormalities, multilineage involvement, unique gene expression profile [upregulation of Homeobox (HOX) genes and CD34 negativity], increased frequency of FLT3-ITD mutations, and favorable prognosis (in the absence of FLT3-ITD) (10) .
Despite this progress, little is known about how NPM1 mutants promote leukemia. The integration of a whole genomic approach including non coding RNAs may lead to an improved understanding of the NPM1 biology. MicroRNAs (MiRNAs) are noncoding RNAs of 19-25 nucleotides in length that regulate gene expression by inducing cleavage or translational inhibition of their targets mRNA through base pairing to partially complementary sites (11) . MiRNAs are involved in controlling cell development and differentiation, as well as apoptosis and proliferation (11) . Recently, miRNAs expression has been linked to hematopoiesis and cancer (12) (13) (14) (15) . Here, we asked whether NPMcϩ (mutated) and NPMcϪ (unmutated) AML cases may differ in their miRNA signature and whether the distinctive gene expression profiling of NPMcϩ AML (CD34 negativity and HOX genes overexpression) (7, 16, 17) may be dictated by a specific miRNA signature. The miRNAs expression in AML with FLT3-ITD and FLT3 active loop mutations was also explored. Hereby, we report a unique miRNA signature associated with NPMcϩ AML and provide evidence that support a role for miRNAs in the regulation of HOX genes in this leukemia subtype. Moreover, we found that miR-155 was strongly but independently associated with FLT3-ITD mutations. Table 2 ). We first compared NPMcϩ to NPMcϪ AML patients using the univariate t test within BRB tools (Class comparison). We found 36 up-regulated and 21 downregulated miRNAs in NPMcϩ NK-AML patients (Table 1) . Among the up-regulated miRNAs in NPMcϩ samples, we identified miR-10a and -b, several let-7 and miR-29 family members along with the miR-15a-16-1 and miR- 17-18a-19a-20a cluster. Additionally, to validate the results of the microarray platform we performed qRT-PCR for the most differentially expressed miRNAs (miR-10a, miR-10b, and miR-22) in 44 AML patients randomly chosen from the initial cohort (28 NPMcϩ and 16 NPMcϪ). As shown in SI Fig. 5 , the qRT-PCR data reproduced the chip results with accuracy. Unsupervised analyses of the data revealed that the AML samples segregated mainly in two main clusters (Fig. 1) . Samples within the cluster 1 ( Fig. 1 Left) had a higher frequency of NPMcϩ than cluster 2 ( Fig. 1 Right) ( 2 P ϭ 0.007). It is noteworthy that miR-10a and miR-10b expression clearly differentiates NPMcϩ vs. NPMcϪ cases.
Results

MiR-10a
Correlates Positively with HOXB4 Expression. Notable the two most up-regulated miRNAs in NPMcϩ AML (miR-10a and miR-10b) are embedded in HOX gene clusters (miR-10a is located between the HOXB4 and HOXB5 gene in chromosome 17q21 and mir-10b between the HOXD3 and HOXD4 gene in chromosome 2q31). It has been reported that in mouse embryos, miR-10a and -10b expression closely follows their host HOX cluster expression during development (19) , suggesting that these miRNAs may be regulated by the same CIS elements that also regulates HOX genes. To investigate whether miR-10a correlated with its flanking HOXB4 gene, we measured miR-10a and HOXB4 in 18 AML patients from the original cohort (NPMcϩ ϭ 9 and NPMcϪ ϭ 9) by qRT-PCR. Indeed, we identified a positive correlation between miR-10a and HOXB4 expression (R ϭ 0.57, P ϭ 0.01, Pearson correlation test). However, no correlation was found between miR-10b and its flanking HOXD3 gene (data not shown).
MiR-204 Targets HOXA10 and MEIS1. Among the down-regulated miRNAs in patients with NPMcϩ AML, there are several miRNAs predicted to interact with HOX genes according to three available ''in silico'' target prediction software [Targetscan (20) , Pictar (21), and RNAhybrid (22)] (SI Table 3 ). Indeed, few miRNAs have been shown to regulate HOX genes and play important roles during early development (14, 19) . We hypothesize that the high HOX genes expression in NPMcϩ AML may be due in part to the downregulation of HOX regulators miRNAs in this subgroup. To start unraveling the role for miRNAs in HOX regulation in NPMcϩ AML, we validated the predicted HOX targets for the downregulated miRNAs in NPMcϩ AML by performing Western blotting using HOXA9, HOXA10, and MEIS1 antibodies in AML cell lines after transfection of the candidate oligonucleotides miRNAs or scrambled oligonucleotides (SI Table 3 and SI Fig. 6 ). To perform this screening, we used the OCI-AML3 cell line (which harbors a NPM1 mutation) (23) and the MEG-01 cell line (both cell lines with high expression of HOXA9, HOXA10, and MEIS1). As shown in Fig. 2 A and oligonucleotides into the MEG-01 cell line. A marked reduction in the luciferase/Renilla ratio was seen for MEIS1 constructs transfected with miR-204 (Fig. 2D ).
CD34 Regulation by miRNAs.
We have previously shown that AML blasts from NPMcϩ patients are frequently CD34 negative (7, 16, 17) . Interestingly, many miRNAs up-regulated in NPMcϩ AML are predicted to target CD34, including miR-9, miR-24, and miR-125a.
To confirm these interactions, we transfected miR-9, miR-24, and miR-125a oligonucleotides or control oligonucleotides into the CD34ϩ AML cell line KG1a using nucleoporation and measured CD34 protein expression using Western blotting. As shown in Fig.  3A , a marked reduction of CD34 protein was evident in the miR-125a transfected cells compared with the scrambled oligonucleotides. To further validated this interaction, we performed luciferase reporter assays, where the 3Ј UTR of the CD34 gene predicted to interact with miR-125a, was cloned in to the luciferase reporter assay and cotransfected with miR-125a oligonucleotide or scrambled oligonucleotides into MEG-01 cell lines using lipofectamine. As shown in Fig. 3B , 85% of reduction in the luciferase normalized ratios was observed in the cells transfected with miR125a compared with the controls.
MiR-155 Is Up-Regulated in FLT3-ITD؉ AML.
Using the univariate t test (BRB), we identified three up-regulated miRNAs (miR-155, miR302a, and miR-133a) in FLT3-ITDϩ as compared with FLT3-wt AML patients. This signature had a FDR of 0% at a significance level of P Ͻ 0.01. Then, we compared the miRNAs expression in FLT3-ITDϩ to FLT3-wt in NPMcϩ patients. Only miR-155 was up-regulated at a significance level of P Ͻ 0.01. We validated the miR-155 up-regulation in FLT3-ITDϩ patients by measuring miR-155 using a different method (qRT-PCR) in a group of 32 randomly chosen AML patients from the original cohort (Fig. 4A ). AML patients with FLT3-TKD mutations were not associated with any distinctive miRNA signature. To further obtain insights about the relationship among FLT3-ITD and miR-155, we carried out an experiment to investigate whether blocking FLT3 signaling using a potent FLT3 inhibitor (SU14813) in two FLT3-ITD positive AML cell lines (MV4-11 and Molt-13) will impact on miR-155 expression (Fig. 4B ). As shown in Fig. 4C and SI Fig. 7 , the miR-155 expression remained unchanged after 48 h of successful FLT3 signaling inhibition in the two cell lines tested. Furthermore we performed an additional control experiment where we generated stable Baf3 cell clones harboring the human FLT3 gene with ITD by using retroviral infection, and measured miR-155 expression in Baf3 wt and in Baf3 FLT3-ITD by Northern blotting (Fig. 4 D and E) . We did not observe any significant difference in miR-155 expression between Baf3 wt and Baf3 FLT3-ITD. In addition, miR-155 expression did not change after treatment of Baf3 FLT3-ITD cells with the FLT3 inhibitor (SU14813) for 48 h (Fig. 4 D and E) .
Discussion
Employing a microarray platform, we systematically analyzed the miRNA expression of AML patients with known subcellular localization/mutation status of NPM1 and identified a strong signature associated with the presence of cytoplasmic mutated nucleophosmin. Among the miRNAs up-regulated in NPMcϩ AML, there were three families of tumor suppressor miRNAs: miR-15-a/miR-16-1, miR-29s (a/b/c), and the let-7 (let-7a, let-7b, and let-7f ). Low level of let-7a has been associated with short survival in lung cancer after surgery (24) , and low level of miR-29b has been associated with shorter survival in CLL (25) . Lysates were generated and an immunoprecipitation was performed with an antibody for FLT3. SDS/PAGE was performed, followed by a Western blot with an antibody for phosphotyrosine. Subsequently, the blot was stripped and reprobed with anti-FLT3. (E ) Northern blotting for miR-155 in BaF3 and Baf3 FLT3-ITD clones incubated for 24 and 48 h with SU14813 or DMSO (control) as described. The blot was stripped and reprobed with U6 for loading control.
